Shots:

• Innovate Biopharmaceuticals announces the initiation of P-III clinical study of INI-202 for Celiac disease with its expected screening & enrollment updates in next few months
• The P-III clinical study is the one of key event for addressing needs of Celiac patients with continued symptoms despite being on a gluten-free diet
• Innovate focuses on developing therapies for autoimmune and inflammatory diseases including its lead candidate larazotide acetate- renormalizing dysfunctional intestinal barrier by reducing intestinal permeability & antigen trafficking

Ref: Innovate Biopharmaceuticals | Image: University of Virginia